Skip to main content
    C

    Cartesian Therapeutics Inc. (RNAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.12
    +0.04 (+0.66%)

    Market Cap: $193.69M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Cartesian Therapeutics Inc. (RNAC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cartesian Therapeutics (RNAC) has a market cap of $193.69M and an enterprise value of $126.84M. It kept -12435.22% of revenue as net income over the last 12 months. Its share count is up 16.56% from a year earlier.

    Total Valuation

    Enterprise value is 34.51% below the market cap, as cash exceeds debt.

    Market Cap$193.69M
    Enterprise Value$126.84M
    Latest price (Nov 17, 2026)$6.12

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.86% in the quarter ended Sep 30, 2026 and grew 18.81% a year over 2 years.

    Shares Outstanding30.31M
    Shares Change (YoY)+16.56%
    Shares Change (QoQ)+2.86%
    Share Count Growth (2Y CAGR)+18.81%

    Valuation Ratios

    The price to sales ratio is 181.0x.

    P/S Ratio181.0x
    Forward P/S462.1x

    Price Statistics

    The stock is down 17.96% over 52 weeks and trades 12.82% below its 50-day average.

    Beta (1Y)1.35
    52-Week Change-17.96%
    1-Month Change+0.66%
    3-Month Change-41.66%
    6-Month Change+0.49%
    5-Year Change-93.98%
    10-Year Change-98.77%
    Total Return (1Y)-17.96%
    Total Return (3Y CAGR)-42.44%
    Total Return (5Y CAGR)-42.75%
    Return vs SPY (1Y)-31.24%
    Max Drawdown (1Y)-42.59%
    Max Drawdown (3Y)-85.58%
    Sharpe Ratio (1Y)-0.27
    Correlation with SPY (1Y)0.23
    50-Day Average$7.02
    200-Day Average$7.61
    52-Week Range$5.60 to $11.00
    RSI (14 Days)39.4
    Average Volume (20 Days)132.75K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 8.38x current liabilities.

    Current Ratio8.38x
    Quick Ratio8.38x

    Returns and Efficiency

    Return on invested capital is 147.21% over the last 12 months, against a 5-year average of 41.05%.

    Return on Assets (ROA)-43.31%
    Return on Invested Capital (ROIC)147.21%
    ROA (5Y Average)-25.70%
    ROIC (5Y Average)41.05%
    Asset Turnover0.00x
    Receivables Turnover8.27x

    Scores

    RNAC has an Altman Z-Score of -4.89, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-4.89
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $1.02M over the last 12 months is down 6.05% from the 12 months before.

    Revenue$1.02M
    Revenue Growth (YoY)-6.05%
    Gross Profit$1.02M
    Operating Income-$159.29M
    Pretax Income-$136.77M
    Net Income-$127.46M
    EBITDA-$135.74M
    Reported EPS (TTM)-$3.58

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$122.97M
    Total Debt$56.13M
    Net Cash$66.85M
    Net Cash Per Share$2.21
    Working Capital$115.80M
    Shareholder Equity-$130.47M
    Tangible Book Value-$272.53M
    Total Assets$294.31M
    Total Liabilities$424.77M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.23M of capital spending, operating cash flow left -$89.89M of free cash flow.

    Operating Cash Flow-$88.66M
    Capital Expenditures$1.23M
    Free Cash Flow-$89.89M
    FCF Per Share-$2.97
    Depreciation and Amortization$2.79M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -15540.88%.

    Gross Margin100.00%
    Operating Margin-15540.88%
    Pretax Margin-13343.41%
    Net Margin-12435.22%
    EBITDA Margin-13243.02%
    FCF Margin-8770.05%

    Growth

    Revenue fell 70.66% a year over 3 years.

    Revenue Growth (3Y CAGR)-70.66%
    Revenue Growth (5Y CAGR)-29.96%

    Revenue and profit by year

    Dividends and Yields

    RNAC does not pay a dividend. Its free cash flow yield is -48.46%.

    FCF Yield-48.46%
    Buyback Yield-12.21%
    Shareholder Yield-12.21%

    Stock Splits

    The last split was a 1-for-30 reverse split on Apr 5, 2024.

    Last Split DateApr 5, 2024
    Split TypeReverse split
    Split Ratio1:30

    Peer Position

    Against 7 similar companies, RNAC has the 2nd highest P/S.

    P/S Ratio181.0x vs 4.3x median
    ROIC147.21% vs -40.30% median
    Revenue Growth (Trailing 4 Quarters, YoY)-6.05% vs -60.81% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -68.04% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-68.04%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RNAC

    What is RNAC's market cap?

    Cartesian Therapeutics has a market cap of $193.69M. Its enterprise value, which adds debt and subtracts cash, is $126.84M.

    How many shares of RNAC are outstanding?

    Cartesian Therapeutics has 30.31M shares outstanding. The count is up 16.56% from a year earlier.

    Does RNAC pay a dividend?

    No. Cartesian Therapeutics does not pay a dividend.

    How much debt does RNAC have?

    Cartesian Therapeutics has $56.13M of total debt and $122.97M of cash and equivalents, a net cash position of $66.85M.